SLAYBACK PHARMA

VIVIMUSTA

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

SLAYBACK PHARMA

Vivimusta HCPCS:

J9056

HCPCS Code Descriptor:

Injection, bendamustine hydrochloride (vivimusta), 1 mg

Category:

J Code

Vivimusta NDCs:

71225-0120-01

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Vivimusta CPT Codes:

-96413 - Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

We have not identified any potential errors with the NDCs mapped to this HCPCS code.

About Vivimusta:

VIVIMUSTA is a Oncology drug manufactured by SLAYBACK PHARMA and administered via the Intravenous route of administration. The J Code: J9056 is aligned to the drug VIVIMUSTA.

VIVIMUSTA is a chemotherapy cancer medication that belongs to the class of drugs known as alkylating antineoplastic agent. This medication attaches to the alkyl group in the cells DNA slowing down and stopping the growth of the cancer cells. VIVIMUSTA is manufactured by Slayback pharmaceuticals and is aligned to the HCPCS code J9056.

ACCESS PRICING AND MORE BY REGISTERING

J9056 Added Date:

July 1, 2023

J9056 Effective Date:

July 1, 2023

J9056 Termination Date:

HCPCS Active

View a Vivimusta billing and coding guide at the link below:
Our team did not identify a source for Vivimusta patient assistance information. Please reach out to our team if you feel that this is a mistake.
VIVIMUSTA prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for VIVIMUSTA. Please check back in a few weeks.